Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193263 | 0.89 | ALDH1A1 (0.48) | BACE1AURKAKDM4ENPC1ALDH1A1 | |
| SCHEMBL10192951 | 0.86 | BACE1 (0.48) | BACE1AURKABACE2 | |
| SCHEMBL10194914 | 0.86 | ALDH1A1 (0.43) | BACE1KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL10193944 | 0.86 | KDM4E (0.43) | BACE1BACE2KDM4ENPC1ALDH1A1 | |
| SCHEMBL10193848 | 0.83 | BACE1 (0.43) | BACE1BACE2KDM4ENPC1ALDH1A1 | |
| SCHEMBL10193025 | 0.79 | BACE1 (0.53) | BACE1AURKABACE2SIRT6 | |
| SCHEMBL10193220 | 0.75 | SMN1; SMN2 (0.49) | BACE1AURKAKDM4ENPC1ALDH1A1 | |
| SCHEMBL10193245 | 0.74 | BACE1 (0.49) | BACE1BACE2 | |
| SCHEMBL10194199 | 0.73 | ALDH1A1 (0.38) | KDM4ENPC1ALDH1A1HPGDTSHR | |
| SCHEMBL10193249 | 0.72 | BACE1 (0.43) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | BACE1 1/4885AURKA 4453/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.